United Kingdom

SanBio Co Ltd (4592.T)

4592.T on Tokyo Stock Exchange

20 Jul 2018
Change (% chg)

¥56 (+2.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


SanBio Company Limited is a Japan-based company primarily engaged in the research and development of regenerative cells drugs. The Company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular... (more)


Beta: --
Market Cap(Mil.): ¥83,119.16
Shares Outstanding(Mil.): 45.42
Dividend: --
Yield (%): --


  4592.T Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -65.57 -- --
ROI: -57.07 2.22 14.61
ROE: -76.57 3.86 16.34

BRIEF-SanBio announces exercise of options

* Says 4,000 units of its 13th series options were exercised to 400,000 shares of its common stock from April 9 to April 10

10 Apr 2018

BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment

* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan

14 Feb 2018

BRIEF-SanBio and unit receive subsidy of $4.5 mln from CIRM

* Says it and unit SanBio, Inc., received subsidy of $4.5 million from CIRM, for chronic cerebral infarction related clinical trials, on Jan. 26 (the U.S. time)

29 Jan 2018

Earnings vs. Estimates